GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A1334 Mosapride CitrateTarget: 5-HT3 Receptors|5-HT4 ReceptorsSummary: 5-HT receptor agonist
-
A2436 Fluoxetine HClTarget: Serotonin (5-HT) reuptakeSummary: Serotonin reuptake inhibitor,selective
-
A5294 Sumatriptan SuccinateTarget: 5-HT1 ReceptorsSummary: 5-HT1 receptor agonist
-
A3317 Clozapine N-oxide (CNO)1 CitationTarget: DREADD LigandsSummary: Metabolite of clozapine, used in chemogenetics.
-
A3811 SEA04004 CitationTarget: Na /Ca2 Exchangers (NCXs)Summary: Specific inhibitor of Na+/Ca2+ exchange
-
B1198 CisaprideTarget: Voltage-gated Potassium (KV) Channels|5-HT4 ReceptorSummary: 5-HT4 receptor agonist
-
B1477 Lurasidone HClTarget: 5-HT2 Receptors|D2 Receptors|5-HT1 Receptors|5-HT7 ReceptorsSummary: Dopamine D2/5-HT2A/5-HT7/5-HT1A inhibitor
-
B2258 Tropisetron HydrochlorideTarget: 5-HT3 ReceptorsSummary: 5-HT3 receptor antagonist
-
B1206 PizotifenTarget: 5-HT2 ReceptorsSummary: Highly selective 5-HT receptor blocking agent
-
B2007 Pizotifen MalateTarget: 5-HT2 Receptors|D2 ReceptorsSummary: 5-HT receptor antagonist